RxDoctor Payments Data

Suzanne Lekson, MD

Internal Medicine · Cincinnati, OHNPI 1942242813

Payments from drug & device makers

$2,383in general payments, 2019–2025

Across 50 payments — averaging $47.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$723
  • GSK$278
  • Bayer$253
  • Boston Scientific$241
  • Novo Nordisk$177
  • Abbott$149
  • plus $563 from 11 others

What the payments were for

  • Food & beverage$2,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,383 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$58,364
Medicare patients
109
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide65$72,000
OzempicSemaglutide43$39,965
EliquisApixaban38$38,972
XareltoRivaroxaban40$20,883
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$19,239
JanuviaSitagliptin Phosphate12$17,485
JardianceEmpagliflozin13$15,516
KerendiaFinerenone20$14,386
FarxigaDapagliflozin Propanediol13$11,148
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$6,435
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$4,597
Atorvastatin Calcium495$4,166
SymbicortBudesonide/Formoterol Fumarate15$3,411
Levothyroxine Sodium207$2,175
Gabapentin125$2,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$14$72,00065 claims
Novo NordiskOzempic$177$39,96543 claims
PfizerEliquis$40$38,97238 claims
Boehringer IngelheimJardiance$14$15,51613 claims
AstraZenecaFarxiga, Symbicort$723$14,55928 claims
BayerKerendia$253$14,38620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →